Traditional Medicine in National Health Policy: A Guide (2026)

Traditional medicine in national health policy means a government deliberately bringing indigenous healing knowledge, practitioners and herbal products into the health system through written policy, law, regulation, financing and service design. WHO estimates that 170 of its 194 Member States, around 88%, use traditional medicine, so what a country decides to recognise changes who actually gets treated.

This guide is written for ministry officials drafting their first policy, for researchers working on health systems integration, and for practitioners who want to know what legal recognition actually requires. It covers what a policy must contain, how safety and quality get protected, and where integration tends to break down.

Nothing here is medical advice. Questions about your own treatment belong with a doctor or a pharmacist who can see your history.

What Is Traditional Medicine’s Role in National Health Policy?

Traditional medicine in national health policy covers the use of remedies and practices that are native to a country, passed down through families and communities, and grounded in local knowledge rather than in laboratory research.

WHO bundles this with non-native practices under the label traditional and complementary medicine, or T&CM. The distinction matters for policy because the two categories attract different regulatory responses: one is treated as cultural heritage to be respected and protected, the other as a product or service to be tested and licensed.

Three things get confused constantly in policy debates, and keeping them apart makes everything downstream clearer.

• Traditional medicine is the indigenous knowledge base: herbal preparations, manual therapy, traditional birth care, spiritual and community healing, and the diagnostic ideas that go with them.
• Biomedical healthcare is the imported or dominant system built on clinical trials, laboratory science and standardised protocols.
• Unproven folk remedies are things people use without a documented tradition of careful dosing, ingredient identity or record-keeping. Some traditional practices sit here too. Policy has to allow for that rather than assume everything indigenous is proven.

So why does this need national policy at all? Because two problems sit side by side. On one side, people already use these treatments constantly, often as their first or only contact with care, and mostly outside the health system’s records. On the other, the products they buy may be adulterated, mislabelled or interacting with prescribed medicine. A policy that only regulates, without improving access, drives practice underground. A policy that only legitimises, without safety rules, puts patients at risk.

African countries work through this with a specific mix of herbal practice, traditional birth attendants, faith healing and community-based treatment, and those are not interchangeable with one another or with any one herb’s evidence base.

Why African Countries Consider Traditional Medicine

The policy case is mostly about reach, cost and trust, not about replacing anything.

Biomedical services are unevenly distributed. The practical reality in much of Africa is that the nearest clinic with staff and equipment is a long trip. Traditional practitioners are frequently closer, and in rural districts they may be the only provider within walking distance.

Out-of-pocket spending shapes who gets care. Public health financing in many low- and middle-income countries still leaves households paying at the point of use. Where a household has to choose between a consultation fee at a distant facility and a local herbalist, policy that recognises both routes can widen access rather than narrow it.

Primary health care is a national target. Universal health coverage (UHC) frameworks usually measure service coverage from the primary care level outward. If most first contact happens outside formal facilities, a health system that ignores that is measuring a fraction of the care it is responsible for.

Patient trust is real data. A person who distrusts the clinic will not come to the clinic. Community trust in a healer is not irrationality; it is a signal about how health services have been delivered in that community.

Local knowledge is a research asset. Long-term observation of a plant’s use across generations is a starting point for study, not a substitute for it. The number is striking: WHO’s International Clinical Trials Registry Platform (ICTRP) lists 4,778 traditional medicine clinical trials, 165 of them restricted to COVID-19.

The counterweight is equally important. Policy language that celebrates indigenous knowledge without qualification tends to produce two failures: regulators who cannot justify enforcement, and practitioners who are told a remedy is proven when the evidence supports only a narrow indication.

How Traditional Medicine in National Health Policy Is Evaluated

Evaluation happens across four evidence tiers, and policy documents fail when they blur them.

Traditional knowledge and documented use

This is the recorded pattern of use: which plant, which part, what preparation, what dose, for what condition, in which community, over how many generations. It tells you what people actually do. It does not by itself tell you the remedy works or is safe, and a policy that treats documented use as proof is making an error.

Preclinical and laboratory findings

Extracts tested in vitro or in animals. Useful for identifying which plant to study further and for flagging toxicity signals, but animal and cell results rarely predict what happens in a human being at a real dose.

Observational and clinical evidence

Structured records from clinics, cohort studies and case series. These show what happened in practice, including adverse effects, but without a comparison group it is hard to separate the treatment from the natural course of the illness.

Controlled trials

Randomised and controlled studies remain the strongest evidence for whether an intervention works better than doing nothing or doing something else. They are also the hardest tier in traditional medicine, because preparation methods vary between communities and a preparation from one village may not be the preparation under trial.

National research institutes exist largely to move work between these tiers. WHO’s 2019 global report recorded 75 Member States with a national research institute for traditional and complementary medicine, fully or partially government funded.

A policy that funds only a laboratory, and not the clinics that record real-world outcomes, will only ever see the tier that matters least for ordinary patients.

What Should a National Policy Include?

A workable national policy document contains a defined set of components. Each one answers a question the health system cannot leave open.

1. A definition of what is being regulated. Which systems, which products and which practitioners fall inside the policy. Without this, every later clause is ambiguous.
2. Recognition of traditional practitioners. A named place for practitioners within the health system’s governance, with a route for existing healers to enter it.
3. A knowledge-protection policy. How community-held knowledge is recorded, who owns it and what happens when it is turned into a product.
4. Practitioner standards. Registration criteria, training requirements, a code of conduct and a complaints process.
5. Product quality and labelling rules. Ingredient identity, permitted adulterants or fillers, testing for contamination, and what the label must state.
6. Safety surveillance. A pharmacovigilance route so adverse reactions to herbal preparations are reported and reviewed.
7. Research support. Funding, priority disease areas, a clinical trials registry and access to laboratories.
8. Referral pathways. When and how a patient moves from a traditional practitioner to a facility, and how the reverse works.
9. Funding and reimbursement rules. Whether services are public, subsidised, reimbursed by insurance or paid out of pocket.

One distinction trips up almost every reader: recognition, registration, licensing and reimbursement are four different levels, not four words for the same thing.

• Recognition means the state acknowledges the practice exists. It costs nothing and changes little.
• Registration means practitioners are entered in a national register, which gives them identity and sometimes limited public-sector roles.
• Licensing adds a defined standard of training and competency before someone may practise in the public system.
• Reimbursement means a funder pays for the service, which is what actually determines whether a poor household can use it.

WHO’s 2019 figures show how uneven this gets: 98 countries reported a national policy on traditional and complementary medicine and 107 had a national office, but the number with a legal and regulatory framework rose from 79 in 2012 to 109 by 2018. Policy on paper, then, moves faster than law.

How Can Safety and Quality Be Protected?

Safety protection is mostly unglamorous, and that is fine. These are the safeguards that work.

• Accurate ingredient identification. Many problems start with the wrong plant in the basket, or a substitute that looks similar and behaves differently. Botanical identification has to be verified rather than assumed from a trade name.
• Contamination testing. Heavy metals, pesticide residues, microbial contamination and adulteration with undeclared pharmaceuticals are recurring findings in herbal product surveys. Testing needs to happen before a product reaches market and continue afterwards.
• Clear labelling. A label should carry the plant name, the part used, the preparation method and a warning where appropriate. Claims that cannot be supported are the fastest route to a consumer being harmed.
• Adverse-event reporting. Herbal preparations go largely unreported, so signal detection depends on practitioners and pharmacists being willing and able to file a report without exposure. A system nobody can use detects nothing.
• Explicit warnings. Pregnancy, children, older adults, liver or kidney disease, and interactions with prescribed medicines are the standard risk groups. Policy should require these warnings and the training to give them accurately.

Those are policy principles, not instructions for treating yourself. A person on regular medication who wants to use a herbal preparation should ask a pharmacist or doctor about interaction risk before they start, and that conversation should be easier to have in a country where the preparation is properly labelled.

How Can Traditional Medicine Work with Formal Health Services?

The working version of collaboration is a referral protocol, not a takeover.

Consider a patient who has been treated for several weeks by a herbalist for persistent abdominal pain, fever that has not settled and weight loss. The herb may be doing nothing, the diagnosis may be wrong, or the person may have tuberculosis, a parasite or a malignancy that needs investigation this month. A referral protocol makes the practitioner a partner in the outcome rather than a competitor for it: red-flag symptoms such as unexplained weight loss, a persistent fever, bleeding, a breast lump or severe breathlessness prompt a same-day referral to a facility, with transport support and no penalty to the practitioner for making the call.

Reformers have found the practical forms this takes.

Cross-training in both directions

Biomedical staff learn enough to refer well and to avoid dismissing patients. Practitioners learn symptom recognition, dosing discipline, infection control and record-keeping. Practitioner-side commentary consistently frames success as dependent on legal and regulatory development rather than on clinical goodwill alone.

Intercultural adaptation of services

Latin American health systems have gone furthest on this and the instruments are named and checkable. Ecuador’s Technical Guide for Culturally Appropriate Childbirth Care and Guatemala’s Manual for Cultural Adaptation of Vertical Childbirth set out how a facility can accommodate traditional practice, including bilingual facilitators, traditional midwives, companion support and delivery positions that follow local custom.

Integration where the evidence supports it

China is the most-cited case, with roughly 40% of all health services delivered in the country originating from traditional medicine. Vietnam works with dual-paradigm clinical guidelines; India runs traditional systems alongside biomedical services through the Ministry of AYUSH; Thailand set out to integrate traditional medicine into mainstream care. All eleven countries in the WHO South-East Asia Region now have national traditional medicine policies, and nine have formal practitioner training and education.

Protection against misleading claims

Collaboration fails quickly if integration becomes a marketing channel. Regulators need to police claims made by both sides, not only by practitioners outside the system.

One honest tension sits underneath all of this. Practitioner recognition can be a barrier: registration fees, exams and paperwork that assume years of formal schooling push informal healers further underground, where a patient is even less protected. Policies that list a system by name without addressing the thousands of unregistered folk healers underneath it mostly regulate a small minority and leave everyone else where they were.

Who Should Participate in Policy Development?

A policy written only by the ministry tends to fail on implementation, because the people who have to deliver it were not in the room.

The stakeholder map includes ministries of health and their traditional medicine units, national regulators and drug control authorities, public health researchers and universities, clinicians and pharmacists, public health professionals and health economists, traditional practitioners and the associations that represent them, knowledge holders and custodians of community knowledge, community organisations, patients, and the environmental and wildlife bodies responsible for plant protection.

Three conditions separate meaningful participation from a consultation that changes nothing. Practitioners need a seat with voting weight where practitioner standards are set, not an invitation to comment after the draft is finished. Communities need prior informed consent, not just notice, before their knowledge enters a database or a pharmacopoeia. And benefit sharing has to be written down, which is where international instruments such as the Nagoya Protocol become relevant, because a national policy is exactly the kind of public instrument that can create access rights to knowledge held privately by a community.

The ownership question is sharper than most policy documents admit. Once a community’s plant knowledge is written into an official monograph, someone owns that text and someone owns the right to use it. Communities reasonably ask who that turns out to be, and whether the answer was negotiated rather than inherited from whoever documented it first.

What Barriers Must African Health Systems Address?

Regulation that exists on paper and is not enforced is the most common failure, and it is the most dangerous one because it produces the appearance of safety without the substance.

Weak laboratory and surveillance capacity

Testing for contamination requires equipment, trained staff and reliable supply. Without those, quality rules are unenforceable. The realistic response is to build regional and shared laboratory capacity rather than to write a standard that nothing can verify.

Inconsistent product quality and informal sales

Where remedies move through informal markets with no batch identity, a quality problem cannot be traced to a source. Minimum labelling and batch requirements do more here than advertising campaigns about buying carefully.

Stigma and professional bias

Clinicians who believe traditional practice is worthless do not refer to it, and patients report being dismissed rather than listened to. Bias inside the health system is a patient-safety problem, not a professional courtesy issue.

Recognition without remuneration

An integrated practitioner with no pay rise and no career route will not stay integrated. This is why recognition has to be paired with funding or reimbursement or the best practitioners leave the programme.

Exploitation of traditional knowledge

Biodiversity pressure runs alongside it. More than two-thirds of the roughly 50,000 medicinal plants in use are still harvested from the wild, and between 4,000 and 10,000 may now be endangered. Communities that harvest and sell these plants carry the cost of a national policy they did not set.

Overclaiming from limited evidence

The most avoidable error: a pilot study becomes a national claim. A remedy tested for one symptom should be described as tested for that symptom. Overclaiming is how support for policy erodes faster than any safety incident.

Frequently Asked Questions

Conclusion

Forty African countries have now developed national traditional medicine policies, and 39 have practitioner regulatory frameworks compared with one in 2000. The direction of travel is clear, and the content of those policies is where the real variation lies.

The ones that hold up start the same way: recognise community knowledge on its own terms, define precisely what is being regulated, build safety and laboratory capacity that can actually be enforced, write referral pathways that respect both professions, and give practitioners a reason to participate beyond being tolerated. Forty countries in national health policy is a beginning; the number that hold up in a clinic a decade from now depends on those five things.